-
-
Overview
-
Specificity: Detects human CTLA-4. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Ipilimumab.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Isotype Control: Bulk Human IgG1 Isotype Control (IB1) [ICH2254]
Endotoxin: ≤ 0.75 EU/mg as determined by the LAL methodPlease contact us at for specific academic pricing.
Background
Ipilimumab biosimilar is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab biosimilar is an IgG1 kappa immunoglobulin with an approximate molecular weight of 148 kDa. Ipilimumab biosimilar is produced in mammalian (Chinese hamster ovary) cell culture.
-
- Properties
-
Overview